USE OF MO-99
Annually, around 30 million medical procedures are performed worldwide using Technetium-99m isotope (Tc-99m), which has decay half-life of about 6 hours. Isotope is injected into the body for the purpose of early diagnosis of oncological, cardiovascular and many other diseases. Medical institutions use specially designed isotope storage devices and convenient devices - generators, which are Тс-99m, source formed during Mo-99 decay. But since the latter has a relatively short decay half-life (66 hours), it is impossible to create its inventories. It is necessary to organize its reliable and continuous supplies (once a week or in some cases even more often) to specialized clinics.
TERMINATION OF HEAT USE
GROWTH OF MO-99 CONSUMPTION
Russia and the United States have been working for more than three decades to reduce the use of HEU in the civilian sector in order to reduce the risk of nuclear proliferation and nuclear terrorism. The center for joint efforts with IAEA participation over the last 10 years is project for transfer of Research Reactors built according to Soviet projects abroad to the use of HEU fuel. SC Rosatom and the US Department of Energy are also cooperating in feasibility study of conversion of some Research Reactors in Russia. Construction of Low-Enriched Fuel Reactors is fully in line with the world trends in nuclear safety and antiterrorism threat.
TO DATE, IT HAS BEEN MASTERED ISOTOPE MANUFACTURING TECHNOLOGY
Solution Reactor ARGUS for production of MOLYBDENUM-99
Our business initiative responds to the efforts of developed countries towards the global human health support. our solution is in line with the current policy of non-proliferation of nuclear weapons for reasones of the maximum security and peaceful nature of innovation. METR LLC posses an innovative research solution for Mo-99 production method and concentrates its efforts on the optimal implementation of the most advanced developments of Russian Nuclear Industry Grants - SRC Kurchatov Institute (Moscow) and JSC SRC RF-FEI (Obninsk).
The essence of innovation lies in use of a Solution Reactor operating at low-enriched uranium raw materials for radioisotope production.. The obsolete way ofr Mo-99 separation from highly enriched feedstock is inferior to the proposed method by all indicators. The production technology meets international safety requirements and relevant international legislation. The project received positive legal and commercial assessments from IAEA specialists.